Novocure Share Price (NASDAQ: NVCR)

$12.34

▲

0.31

(2.58%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Novocure Stock chart to analyse performance

Novocure stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$12.10
Today's High:$12.46
$12.34
1.94%
Downside
Day's Volatility :2.89%
Upside
0.96%
52 Weeks Low:$10.87
52 Weeks High:$34.13
$12.34
11.91%
Downside
52 Weeks Volatility :68.15%
Upside
63.84%

Novocure Stock Returns

Period	Novocure Limited	Sector (Health Care)	Index (Russel 2000)
3 Months	-27.76%	3.6%	0.0%
6 Months	-33.13%	-7.7%	0.0%
1 Year	-26.51%	-12.6%	0.0%
3 Years	-84.37%	9.5%	-4.7%

Novocure Limited Key Stats

Check Novocure key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$12.03
Open	$12.26
Today's High	$12.46
Today's Low	$12.1
Market Capitalization	$1.3B
Today's Volume	$1.0M
52 Week High	$34.13
52 Week Low	$10.87
Revenue TTM	$630.2M
EBITDA	$-158.9M
Earnings Per Share (EPS)	$-1.56
Profit Margin	-27.13%
Quarterly Earnings Growth YOY	-0.06%
Return On Equity TTM	-48.07%

Stock Returns calculator for Novocure Stock including INR - Dollar returns

The Novocure stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Novocure investment value today

Current value as on today

₹68,761

Returns

₹31,239

(-31.24%)

Returns from Novocure Stock

₹36,523 (-36.52%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Novocure Stock

129%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Novocure Stock from India on INDmoney has increased by 129% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Novocure Limited

Name
Holdings %
Name
Holdings %
FMR Inc
14.75%
BlackRock Inc
11.65%
Vanguard Group Inc
9.62%
Soleus Capital Management, L.P.
6.18%
Capital World Investors
5.71%
State Street Corp
2.32%

Analyst Recommendation on Novocure Stock

Rating

Trend

Buy

61%Buy

38%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Novocure(by analysts ranked 0 to 5 stars)

Novocure Share Price Target

What analysts predicted

Upside of 120.32%

Target:

$27.19

Current:

$12.34

Novocure share price target is $27.19, a slight Upside of 120.32% compared to current price of $12.34 as per analysts' prediction.

Novocure Stock Insights

Price Movement
In the last 3 months, NVCR stock has moved down by -35.6%
Increasing Revenue
Revenue is up for the last 2 quarters, 154.99M → 158.80M (in $), with an average increase of 2.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -34.31M → -40.13M (in $), with an average decrease of 17.0% per quarter
NVCR vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 29.0% return, outperforming this stock by 65.7%
NVCR vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 163.5% return, outperforming this stock by 248.3%
Price to Sales
ForNVCR every $1 of sales, investors are willing to pay $2.1, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Novocure Limited Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$351.3M	↑ 41.62%
Net Income	$-7.2M	↓ 88.62%
Net Profit Margin	-2.06%	↑ 23.56%

	FY20	Y/Y Change
Revenue	$494.4M	↑ 40.72%
Net Income	$19.8M	↓ 373.97%
Net Profit Margin	4.01%	↑ 6.07%

	FY21	Y/Y Change
Revenue	$535.0M	↑ 8.23%
Net Income	$-58.4M	↓ 394.58%
Net Profit Margin	-10.91%	↓ 14.92%

	FY22	Y/Y Change
Revenue	$537.8M	↑ 0.53%
Net Income	$-92.5M	↑ 58.58%
Net Profit Margin	-17.2%	↓ 6.29%

	FY23	Y/Y Change
Revenue	$509.3M	↓ 5.3%
Net Income	$-207.0M	↑ 123.75%
Net Profit Margin	-40.65%	↓ 23.45%

	FY24	Y/Y Change
Revenue	$605.2M	↑ 18.82%
Net Income	$-168.6M	↓ 18.55%
Net Profit Margin	-27.86%	↑ 12.79%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$138.5M	↑ 3.53%
Net Income	$-38.8M	↓ 17.67%
Net Profit Margin	-27.98%	↑ 7.21%

	Q2 FY24	Q/Q Change
Revenue	$150.4M	↑ 8.56%
Net Income	$-33.4M	↓ 13.89%
Net Profit Margin	-22.2%	↑ 5.78%

	Q3 FY24	Q/Q Change
Revenue	$155.1M	↑ 3.15%
Net Income	$-30.6M	↓ 8.4%
Net Profit Margin	-19.71%	↑ 2.49%

	Q4 FY24	Q/Q Change
Revenue	$161.3M	↑ 3.98%
Net Income	$-65.9M	↑ 115.64%
Net Profit Margin	-40.88%	↓ 21.17%

	Q1 FY25	Q/Q Change
Revenue	$155.0M	↓ 3.89%
Net Income	$-34.3M	↓ 47.94%
Net Profit Margin	-22.14%	↑ 18.74%

	Q2 FY25	Q/Q Change
Revenue	$158.8M	↑ 2.46%
Net Income	$-40.1M	↑ 16.96%
Net Profit Margin	-25.28%	↓ 3.14%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$262.7M	↑ 56.36%

	FY20	Y/Y Change
Profit	$387.9M	↑ 47.64%

	FY21	Y/Y Change
Profit	$420.2M	↑ 8.32%

	FY22	Y/Y Change
Profit	$423.0M	↑ 0.67%

	FY23	Y/Y Change
Profit	$381.1M	↓ 9.91%

	FY24	Y/Y Change
Profit	$468.0M	↑ 22.83%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$104.8M	↑ 3.54%

	Q2 FY24	Q/Q Change
Profit	$115.7M	↑ 10.39%

	Q3 FY24	Q/Q Change
Profit	$119.7M	↑ 3.48%

	Q4 FY24	Q/Q Change
Profit	$127.8M	↑ 6.75%

	Q1 FY25	Q/Q Change
Profit	$116.5M	↓ 8.86%

	Q2 FY25	Q/Q Change
Profit	$117.3M	↑ 0.74%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$26.6M	↓ 1527.35%
Investing Cash Flow	$-51.7M	↑ 840.6%
Financing Cash Flow	$61.7M	↓ 11.08%

	FY20	Y/Y Change
Operating Cash Flow	$99.1M	↑ 272.46%
Investing Cash Flow	$-472.8M	↑ 815.18%
Financing Cash Flow	$440.2M	↑ 613.69%

	FY21	Y/Y Change
Operating Cash Flow	$82.8M	↓ 16.53%
Investing Cash Flow	$-144.8M	↓ 69.37%
Financing Cash Flow	$25.7M	↓ 94.16%

	FY22	Y/Y Change
Operating Cash Flow	$30.8M	↓ 62.8%
Investing Cash Flow	$-140.0M	↓ 3.37%
Financing Cash Flow	$15.5M	↓ 39.73%

	FY23	Y/Y Change
Operating Cash Flow	$-73.3M	↓ 338.2%
Investing Cash Flow	$184.1M	↓ 231.57%
Financing Cash Flow	$15.8M	↑ 1.91%

	FY24	Y/Y Change
Operating Cash Flow	$-26.4M	↓ 64.04%
Investing Cash Flow	$-140.2M	↓ 176.16%
Financing Cash Flow	$90.3M	↑ 472.08%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-31.6M	↑ 116.88%
Investing Cash Flow	$246.2M	↑ 149.97%
Financing Cash Flow	$213.0K	↓ 88.85%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-1.7M	↓ 94.55%
Investing Cash Flow	$-374.4M	↓ 252.08%
Financing Cash Flow	$87.3M	↑ 40893.9%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$10.4M	↓ 703.26%
Investing Cash Flow	$10.2M	↓ 102.72%
Financing Cash Flow	$100.0K	↓ 99.89%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-3.5M	↓ 133.26%
Investing Cash Flow	$-22.2M	↓ 317.9%
Financing Cash Flow	$2.7M	↑ 2585.0%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-35.7M	↑ 933.47%
Investing Cash Flow	$-6.5M	↓ 70.86%
Financing Cash Flow	$5.2M	↑ 95.42%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-15.9M	↓ 55.32%
Investing Cash Flow	$36.0M	↓ 656.03%
Financing Cash Flow	$2.4M	↓ 54.51%

Novocure Technicals Summary

Sell

Neutral

Buy

Novocure is currently in a neutral trading position according to technical analysis indicators.

Novocure Limited Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Novocure Limited	8.75%	-33.13%	-26.51%	-84.37%	-85.46%
Medtronic Plc	3.87%	-1.59%	4.32%	4.82%	-13.69%
Edwards Lifesciences Corp.	2.55%	13.95%	18.33%	-9.73%	-5.31%
Boston Scientific Corp.	0.09%	0.6%	30.02%	157.38%	154.4%
Stryker Corporation	3.63%	-0.85%	8.87%	89.43%	97.71%
Abbott Laboratories	5.15%	-5.37%	15.72%	26.56%	24.53%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Novocure Limited	NA	NA	-0.47	-1.58	-0.48	-0.09	NA	3.13
Medtronic Plc	25.4	25.4	2.14	5.46	0.1	0.05	0.03	37.36
Edwards Lifesciences Corp.	34.03	34.03	4.85	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	62.95	62.95	1.84	2.98	0.12	0.05	NA	15.14
Stryker Corporation	51.54	51.54	2.24	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.64	16.64	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Novocure Limited	Buy	$1.3B	-85.46%	NA	-27.13%
Medtronic Plc	Buy	$118.0B	-13.69%	25.4	13.63%
Edwards Lifesciences Corp.	Buy	$47.8B	-5.31%	34.03	72.96%
Boston Scientific Corp.	Buy	$156.7B	154.4%	62.95	13.55%
Stryker Corporation	Buy	$149.0B	97.71%	51.54	12.25%
Abbott Laboratories	Buy	$230.9B	24.53%	16.64	32.43%

Novocure Dividend announcements

Novocure Earnings
Novocure’s price-to-earnings ratio stands at None

About Novocure Limited

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Organization	Novocure
Employees	1488
CEO	Ms. Ashley Cordova
Industry	Health Technology

Key Management of Novocure Limited

Name	Title
Mr. William F. Doyle	Executive Chairman
Ms. Ashley Cordova	CEO & Director
Mr. Frank Leonard	President
Mr. Barak Ben-Arye	General Counsel
Dr. Uri Weinberg M.D., Ph.D.	Chief Innovation Officer
Mr. Christoph Brackmann	Chief Financial Officer
Mr. Mukund Paravasthu	Chief Operating Officer
Ms. Ingrid Goldberg	VP of Investor Relations
Mr. Michael Puri	Chief Human Resources Officer
Dr. Nicolas Leupin M.B.A., M.D., Ph.D.	Chief Medical Officer

Important FAQs about investing in NVCR Stock from India :

What is Novocure share price today?

Novocure share price today is $12.34 as on August 30, 2025 at 1:29 am IST at the close of the market. Novocure share today touched a day high of $12.46 and a low of $12.10.

What is the 52 week high and 52 week low for Novocure share?

Novocure share touched a 52 week high of $34.13 and a 52 week low of $10.87. Novocure stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $12.34, lower by 63.84% versus the 52 week high.

How to invest in Novocure Stock (NVCR) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Novocure on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Novocure Shares that will get you 0.1216 shares as per Novocure share price of $12.34 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Novocure Stock (NVCR) from India?

Indian investors can start investing in Novocure (NVCR) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Novocure stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Novocure share’s latest price of $12.34 as on August 30, 2025 at 1:29 am IST, you will get 0.8104 shares of Novocure. Learn more about fractional shares .

What are the returns that Novocure has given to Indian investors in the last 5 years?

Novocure stock has given -85.46% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?